0001209191-22-033597.txt : 20220602 0001209191-22-033597.hdr.sgml : 20220602 20220602170516 ACCESSION NUMBER: 0001209191-22-033597 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20220602 DATE AS OF CHANGE: 20220602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hearne Michael S CENTRAL INDEX KEY: 0001759910 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 22991790 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-715-3600 MAIL ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-31 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001759910 Hearne Michael S C/O LA JOLLA PHARMACEUTICAL COMPANY 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 0 1 0 0 Chief Financial Officer Common Stock 2022-05-31 4 A 0 189 3.4085 A 9714 D Common Stock 9607934 I By LP Employee Stock Option (Right to Buy) 4.01 2022-05-31 4 A 0 189 0.00 A 2032-05-31 Common Stock 189 189 D These shares were acquired on 5/31/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP. The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. /s/ Michael Hearne 2022-06-02